Positron emission tomography imaging of amphetamine-induced dopamine release in the human cortex: A comparative evaluation of the high affinity dopamine D2/3 radiotracers [11C]FLB 457 and [ 11C]fallypride

Synapse

Volumn 63, Issue 6, 2009, Pages 447-461

  Narendran, Rajesh ^a,e   Frankle, W Gordon ^a   Mason, N Scott ^a   Rabiner, Eugenii A ^b   Gunn, Roger N ^b   Searle, Graham E ^b   Vora, Shivangi ^a   Litschge, Maralee ^a   Kendro, Steve ^a   Cooper, Thomas B ^c   Mathis, Chester A ^a   Laruelle, Marc ^b,d  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b GLAXOSMITHKLINE   (United Kingdom)

^c Och Spine at New York Presbyterian Hospitals   (United States)

^d IMPERIAL COLLEGE LONDON   (United Kingdom)

^e PRESBYTERIAN UNIVERSITY HOSPITAL   (United States)

Author keywords

11C fallypride; 11C FLB 457; Amphetamine and human cortex; Dopamine; PET

Indexed keywords

AMPHETAMINE; DOPAMINE; DOPAMINE 2 RECEPTOR; DOPAMINE 3 RECEPTOR; FALLYPRIDE C 11; ISOREMOXIPRIDE; ISOREMOXIPRIDE C 11; TRACER; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BINDING AFFINITY; BRAIN CORTEX; CEREBELLUM; CINGULATE GYRUS; CONTROLLED STUDY; DOPAMINE RELEASE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; HUMAN; HUMAN EXPERIMENT; MOLECULAR IMAGING; NORMAL HUMAN; OCCIPITAL CORTEX; PARIETAL LOBE; POSITRON EMISSION TOMOGRAPHY; PREFRONTAL CORTEX; PRIORITY JOURNAL; RECEPTOR BINDING; RECEPTOR OCCUPANCY; TEMPORAL CORTEX; TEMPORAL LOBE;

ADULT; AMPHETAMINE; ARTIFACTS; BENZAMIDES; BINDING, COMPETITIVE; CEREBRAL CORTEX; DOPAMINE; DOPAMINE ANTAGONISTS; DOPAMINE UPTAKE INHIBITORS; FEMALE; HUMANS; MALE; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY; PYRROLIDINES; RECEPTORS, DOPAMINE D2; RECEPTORS, DOPAMINE D3; SALICYLAMIDES; SYNAPTIC TRANSMISSION; YOUNG ADULT;

EID: 66149192549     PISSN: 08874476     EISSN: 10982396     Source Type: Journal    
DOI: 10.1002/syn.20628     Document Type: Article

References (79)

1. Aalto S, Bruck A, Laine M, Nagren K, Rinne JO. 2005. Frontal and temporal dopamine release during working memory and attention tasks in healthy humans: A positron emission tomography study using the high-affinity dopamine D2 receptor ligand [11C]FLB 457. J Neurosci 25:2471-2477.
2. Abi-Dargham A, Laruelle M, Seibyl J, Rattner Z, Baldwin RM, Zoghbi SS, Zea-Ponce Y, Bremner JD, Hyde TM, Charney DS, Hoffer PB, Innis RB. 1994. SPECT measurement of benzodiazepine receptors in human brain with [123-I]iomazenil: Kinetic and equilibrium paradigms. J Nucl Med 35:228-238.
3. Abi-Dargham A, Martinez D, Mawlawi O, Simpson N, Hwang DR, Slifstein M, Anjilvel S, Pidcock J, Guo NN, Lombardo I, Mann JJ, Van Heertum R, Foged C, Halldin C, Laruelle M. 2000. Measurement of striatal and extrastriatal dopamine D1 receptor binding potential with [11C]NNC 112 in humans: Validation and reproducibility. J Cereb Blood Flow Metab 20:225-243.
4. Abi-Dargham A, Mawlawi O, Lombardo I, Gil R, Martinez D, Huang Y, Hwang DR, Keilp J, Kochan L, Van Heertum R, Gorman JM, Laruelle M. 2002. Prefrontal dopamine D1 receptors and working memory in schizophrenia. J Neurosci 22:3708-3719.
5. Abi-Dargham A, Simpson N, Kegeles L, Parsey R, Hwang DR, Anjilvel S, Zea-Ponce Y, Lombardo I, Van Heertum R, Mann JJ, Foged C, Halldin C, Laruelle M. 1999. PET studies of binding competition between endogenous dopamine and the D1 radiotracer [11C]NNC 756. Synapse 32:93-109.
6. Ahmad R, Hirani E, Grasby PM, Hume SP. 2006. Effect of reduction in endogenous dopamine on extrastriatal binding of [11C]FLB 457 in rat brain - An ex vivo study. Synapse 59:162-172.
7. Angrist B, Corwin J, Bartlik B, Cooper T. 1987. Early pharmacokinetics and clinical effects of oral D-amphetamine in normal subjects. Biol Psychiatry 22:1357-1368.
8. Asselin MC, Montgomery AJ, Grasby PM, Hume SP. 2007. Quantification of PET studies with the very high-affinity dopamine D2/D3 receptor ligand [11C]FLB 457: Re-evaluation of the validity of using a cerebellar reference region. J Cereb Blood Flow Metab 27:378-392.
9. Benjamini Y, Hochberg Y. 1995. Controlling the false discovery rate: A practical and powerful approach to multiple testing. J R Stat Soc Ser B 57:289-300.
10. Boileau I, Dagher A, Leyton M, Gunn RN, Baker GB, Diksic M, Benkelfat C. 2006. Modeling sensitization to stimulants in humans: An [11C]raclopride/ positron emission tomography study in healthy men. Arch Gen Psychiatry 63:1386-1395.
11. Breier A, Su TP, Saunders R, Carson RE, Kolachana BS, deBartolomeis A, Weinberger DR, Weisenfeld N, Malhotra AK, Eckelman WC, Pickar D. 1997. Schizophrenia is associated with elevated amphetamine-induced synaptic dopamine concentrations: Evidence from a novel positron emission tomography method. Proc Natl Acad Sci USA 94:2569-2574.
12. Cardenas L, Houle S, Kapur S, Busto UE. 2004. Oral D-amphetamine causes prolonged displacement of [11C]raclopride as measured by PET. Synapse 51:27-31.
13. Carson RE, Breier A, deBartolomeis A, Saunders RC, Su TP, Schmall B, Der MG, Pickar D, Eckelman WC. 1997. Quantification of amphetamine-induced changes in [C-11]raclopride binding with continuous infusion. J Cereb Blood Flow Metab 17:437-447.
14. Chou YH, Halldin C, Farde L. 2000. Effect of amphetamine on extrastriatal D2 dopamine receptor binding in the primate brain: A PET study. Synapse 38:138-143.
15. Christian BT, Narayanan T, Shi B, Morris ED, Mantil J, Mukherjee J. 2004. Measuring the in vivo binding parameters of [18F]-fallypride in monkeys using a PET multiple-injection protocol. J Cereb Blood Flow Metab 24:309-322.
16. Cropley VL, Innis RB, Nathan PJ, Brown AK, Sangare JL, Lerner A, Ryu YH, Sprague KE, Pike VW, Fujita M. 2008. Small effect of dopamine release and no effect of dopamine depletion on [(18)F]fallypride binding in healthy humans. Synapse 62:399-408.
17. Delforge J, Bottlaender M, Loc'h C, Dolle F, Syrota A. 2001. Parametric images of the extrastriatal D2 receptor density obtained using a high-affinity ligand (FLB 457) and a double-saturation method. J Cereb Blood Flow Metab 21:1493-1503.
18. Delforge J, Bottlaender M, Loc'h C, Guenther I, Fuseau C, Bendriem B, Syrota A, Maziere B. 1999. Quantitation of extrastriatal D2 receptors using a very high-affinity ligand (FLB 457) and the multi-injection approach. J Cereb Blood Flow Metab 19:533-546.
19. Endres CJ, Kolachana BS, Saunders RC, Su T, Weinberger D, Breier A, Eckelman WC, Carson RE. 1997. Kinetic modeling of [C-11]raclopride: Combined PET-microdialysis studies. J Cereb Blood Flow Metab 17:932-942.
20. Farde L, Suhara T, Nyberg S, Karlsson P, Nakashima Y, Hietala J, Halldin C. 1997. A PET study of [C-11]FLB 457 binding to extrastriatal D-2-dopamine receptors in healthy subjects and antipsychotic drug-treated patients. Psychopharmacology 133:396-404.
21. Gandelman MS, Baldwin RM, Zoghbi SS, Zea-Ponce Y, Innis RB. 1994. Evaluation of ultrafiltration for the free fraction determination of single photon emission computerized tomography (SPECT) radiotracers: β-CIT. IBF and iomazenil. J Pharm Sci 83:1014-1019. (Pubitemid 24228554)
22. Gunn RN, Sargent PA, Bench CJ, Rabiner EA, Osman S, Pike VW, Hume SP, Grasby PM, Lammertsma AA. 1998. Tracer kinetic modeling of the 5-HT1A receptor ligand [carbonyl-11C]WAY-100635 for PET. Neuroimage 8:426-440.
23. Hagelberg N, Aalto S, Kajander J, Oikonen V, Hinkka S, Nagren K, Hietala J, Scheinin H. 2004. Alfentanil increases cortical dopamine D2/D3 receptor binding in healthy subjects. Pain 109:86-93.
24. Hall H, Farde L, Halldin C, Hurd YL, Pauli S, Sedvall G. 1996. Autoradiographic localization of extrastriatal D2-dopamine receptors in the human brain using [125I]epidepride. Synapse 23:115-123.
25. Halldin C, Farde L, Hogberg T, Mohell N, Hall H, Suhara T, Karlsson P, Nakashima Y, Swahn CG. 1995. Carbon-11-FLB 457: A radioligand for extrastriatal D2 dopamine receptors. J Nucl Med 36:1275-1281.
26. Hill AV. 1910. The possible effects of the aggregation of the molecules of haemoglobin on its disassociation curves. Phys Med Biol 1991:749-761.
27. Innis R, Cunningham VJ, Delforge J, Fujioka K, Gjedde A, Gunn R, Holden JE, Houle S, Huang SC, Ichise M, Hidehiro I, Hiroshi I, Yuichi K, Koeppe RA, Knudsen GM, Juhani K, Lammertsma AA, Laruelle M, Logan J, Maguire RP, Mintun M, Morris ED, Parsey RV, Price CJ, M S, Sossi V, Suhara T, Votaw JR, DF W, Carson RE. 2007. Consensus nomenclature for in vivo imaging of reversibly binding radioligands. J Cereb Blood Flow Metab 27:1533-1539.
28. Inoue M, Suhara T, Sudo Y, Okubo Y, Yasuno F, Kishimoto T, Yoshikawa K, Tanada S. 2001. Age-related reduction of extrastriatal dopamine D2 receptor measured by PET. Life Sci 69:1079-1084.
29. Ito H, Sudo Y, Suhara T, Okubo Y, Halldin C, Farde L. 2001. Error analysis for quantification of [(11)C]FLB 457 binding to extrastriatal D(2) dopamine receptors in the human brain. Neuroimage 13:531-539.
30. Kaasinen V, Kemppainen N, Nagren K, Helenius H, Kurki T, Rinne JO. 2002. Age-related loss of extrastriatal dopamine D(2) -like receptors in women. J Neurochem 81:1005-1010.
31. Kaasinen V, Nagren K, Hietala J, Farde L, Rinne JO. 2001. Sex differences in extrastriatal dopamine d(2)-like receptors in the human brain. Am J Psychiatry 158:308-311.
32. Kaasinen V, Nagren K, Hietala J, Oikonen V, Vilkman H, Farde L, Halldin C, Rinne JO. 2000a. Extrastriatal dopamine D2 and D3 receptors in early and advanced Parkinson's disease. Neurology 54:1482-1487.
33. Kaasinen V, Vilkman H, Hietala J, Nagren K, Helenius H, Olsson H, Farde L, Rinne J. 2000b. Age-related dopamine D2/D3 receptor loss in extrastriatal regions of the human brain. Neurobiol Aging 21:683-688.
34. Kegeles LS, Zea-Ponce Y, Abi-Dargham A, Rodenhiser J, Wang T, Weiss R, Van Heertum RL, Mann JJ, Laruelle M. 1999. Stability of [123I]IBZM SPECT measurement of amphetamine-induced striatal dopamine release in humans. Synapse 31:302-308.
35. Kemppainen N, Laine M, Laakso MP, Kaasinen V, Nagren K, Vahlberg T, Kurki T, Rinne JO. 2003. Hippocampal dopamine D2 receptors correlate with memory functions in Alzheimer's disease. Eur J Neurosci 18:149-154.
36. Laruelle M. 2000. Imaging synaptic neurotransmission with in vivo binding competition techniques: A critical review. J Cereb Blood Flow Metab 20:423-451. (Pubitemid 30164887)
37. Laruelle M, Abi-Dargham A, Innis RB. 1998.Imaging receptor occupancy by endogenous transmitters in humans. In: Carson R, Daube-Whiterspoon ME, Herscovith P, editors. Quantitative functional brain imaging with positron emission tomography. San Diego: Academic Press. 455-462.
38. Laruelle M, Abi-Dargham A, van Dyck CH, Gil R, De Souza CD, Erdos J, McCance E, Rosenblatt W, Fingado C, Zoghbi SS, Baldwin RM, Seibyl JP, Krystal JH, Charney DS, Innis RB. 1996. Single photon emission computerized tomography imaging of amphetamine-induced dopamine release in drug free schizophrenic subjects. Proc Natl Acad Sci USA 93:9235-9240.
39. Laruelle M, Abi-Dargham A, van Dyck CH, Rosenblatt W, Zea-Ponce Y, Zoghbi SS, Baldwin RM, Charney DS, Hoffer PB, Kung HF, Innis RB. 1995. SPECT imaging of striatal dopamine release after amphetamine challenge. J Nucl Med 36:1182-1190.
40. Laruelle M, Iyer RN, Al-Tikriti MS, Zea-Ponce Y, Malison R, Zoghbi SS, Baldwin RM, Kung HF, Charney DS, Hoffer PB, Innis RB, Bradberry CW. 1997. Microdialysis and SPECT measurements of amphetamine-induced dopamine release in nonhuman primates. Synapse 25:1-14.
41. 2 receptors in healthy subjects. J Nucl Med 35:743-754.
42. Leyton M, Boileau I, Benkelfat C, Diksic M, Baker G, Dagher A. 2002. Amphetamine-induced increases in extracellular dopamine, drug wanting, and novelty seeking: A PET/[11C]raclopride study in healthy men. Neuropsychopharmacology 27:1027-1035.
43. Malison RT, Mechanic KY, Klummp H. 1999. Reduced amphetamine-stimulated dopamine release in cocaine addicts as measured by [123I]IBZM SPECT. J Nucl Med 40:110.
44. Martinez D, Gil R, Slifstein M, Hwang DR, Huang Y, Perez A, Kegeles L, Talbot P, Evans S, Krystal J, Laruelle M, Abi-Dargham A. 2005. Alcohol dependence is associated with blunted dopamine transmission in the ventral striatum. Biol Psychiatry 58:779-786.
45. Martinez D, Narendran R, Foltin RW, Slifstein M, Hwang DR, Broft A, Huang Y, Cooper TB, Fischman MW, Kleber HD, Laruelle M. 2007. Amphetamine-induced dopamine release: Markedly blunted in cocaine dependence and predictive of the choice to self-administer cocaine. Am J Psychiatry 164:622-629.
46. Martinez D, Slifstein M, Broft A, Mawlawi O, Hwang DR, Huang Y, Cooper T, Kegeles L, Zarahn E, Abi-Dargham A, Haber SN, Laruelle M. 2003. Imaging human mesolimbic dopamine transmission with positron emission tomography. II. Amphetamine-induced dopamine release in the functional subdivisions of the striatum. J Cereb Blood Flow Metab 23:285-300.
47. Melchitzky DS, Lewis DA. 2000. Tyrosine hydroxylase- and dopamine transporter-immunoreactive axons in the primate cerebellum. Evidence for a lobular- and laminar-specific dopamine innervation. Neuropsychopharmacology 22:466-472.
48. Mintun MA, Raichle ME, Kilbourn MR, Wooten GF, Welch MJ. 1984. A quantitative model for the in vivo assessment of drug binding sites with positron emission tomography. Ann Neurol 15:217-227.
49. Montgomery AJ, Asselin MC, Farde L, Grasby PM. 2007. Measurement of methylphenidate-induced change in extrastriatal dopamine concentration using [(11)C]FLB 457 PET. J Cereb Blood Flow Metab 2:369-377.
50. Mukherjee J, Christian BT, Dunigan KA, Shi B, Narayanan TK, Satter M, Mantil J. 2002. Brain imaging of 18F-fallypride in normal volunteers: Blood analysis, distribution, test-retest studies, and preliminary assessment of sensitivity to aging effects on dopamine D-2/D-3 receptors. Synapse 46:170-188.
51. Mukherjee J, Shi B, Christian BT, Chattopadhyay S, Narayanan TK. 2004. 11C-Fallypride: Radiosynthesis and preliminary evaluation of a novel dopamine D2/D3 receptor PET radiotracer in nonhuman primate brain. Bioorg Med Chem 12:95-102.
52. Mukherjee J, Yang ZY, Das MK, Brown T. 1995. Fluorinated benzamide neuroleptics-III. Development of (S)-N-[(1-allyl-2-pyrrolidinyl) methyl]-5-(3-[18F]fluoropropyl)-2,3-dimethoxybenzamide as an improved dopamine D-2 receptor tracer. Nucl Med Biol 22: 283-296.
53. Mukherjee J, Yang ZY, Lew R, Brown T, Kronmal S, Cooper MD, Seiden LS. 1997. Evaluation of d-amphetamine effects on the binding of dopamine D-2 receptor radioligand, F-18-fallypride in nonhuman primates using positron emission tomography. Synapse 27:1-13.
54. Okauchi T, Suhara T, Maeda J, Kawabe K, Obayashi S, Suzuki K. 2001. Effect of endogenous dopamine on endogenous dopamine on extrastriated [(11)C]FLB457 binding measured by PET. Synapse 41:87-95.
55. Okubo Y, Olsson H, Ito H, Lofti M, Suhara T, Halldin C, Farde L. 1999. PET mapping of extrastriatal D2-like dopamine receptors in the human brain using an anatomic standardization technique and [11C]FLB 457. Neuroimage 10:666-674.
56. Olsson H, Halldin C, Farde L. 2004. Differentiation of extrastriatal dopamine D2 receptor density and affinity in the human brain using PET. Neuroimage 22:794-803.
57. Olsson H, Halldin C, Swahn CG, Farde L. 1999. Quantification of [11C]FLB 457 binding to extrastriatal dopamine receptors in the human brain. J Cereb Blood Flow Metab 19:1164-1173.
58. Price JC, Mason S, Lopresti B, Holt D, Simpson NR, Drevets W, Smith GS, Mathis CA. 1997. PET measurements of endogenous neurotransmitter activity using high and low affinity radiotracers. Neuroimage 5:B77.
59. Reimer ML, Mamer OA, Zavitsanos AP, Siddiqui AW, Dadgar D. 1993. Determination of amphetamine, methamphetamine and desmethyldeprenyl in human plasma by gas chromatography/negative ion chemical ionization mass spectrometry. Biol Mass Spectrom 22:235-242.
60. Riccardi P, Li R, Ansari MS, Zald D, Park S, Dawant B, Anderson S, Doop M, Woodward N, Schoenberg E, Schmidt D, Baldwin R, Kessler R. 2006. Amphetamine-induced displacement of [(18)F] fallypride in striatum and extrastriatal regions in humans. Neuropsychopharmacology 31:1016-1026.
61. Slifstein M, Hwang DR, Huang Y, Guo N, Sudo Y, Narendran R, Talbot P, Laruelle M. 2004a. In vivo affinity of [(18)F]fallypride for striatal and extrastriatal dopamine D(2) receptors in nonhuman primates. Psychopharmacology (Berl) 175:274-286.
62. Slifstein M, Kegeles L, Hackett E, Castrillon J, Gonzales R, Bae J, Laruelle M, Abi-Dargham A. 2007a. Effect of amphetamine challenge on the binding of [18F]fallypride in the striatum and extrastriatal brain regions: A study in healthy human volunteers. Paper Presented at the 46th Annual Meeting of the American College of Neuropsychopharmacology, Boca Raton, FL.
63. Slifstein M, Moore H, Kegeles L, Duvall M, Xiaoyan X, Hackett E, Castrillon J, Kambalov O, Scher E, Laruelle M, Abi-Dargham A. 2007b. Correlation between PET and microdialysis measurements of amphetamine induced DA release in striatal and extrastriatal brain regions in baboons. 48 (Suppl 2):113.
64. Slifstein M, Narendran R, Hwang DR, Sudo Y, Talbot PS, Huang Y, Laruelle M. 2004b. Effect of amphetamine on [(18)F]fallypride in vivo binding to D(2) receptors in striatal and extrastriatal regions of the primate brain: Single bolus and bolus plus constant infusion studies. Synapse 54:46-63.
65. Smith SM, Jenkinson M, Woolrich MW, Beckmann CF, Behrens TE, Johansen-Berg H, Bannister PR, De Luca M, Drobnjak I, Flitney DE, Niazy RK, Saunders J, Vickers J, Zhang Y, De Stefano N, Brady JM, Matthews PM. 2004. Advances in functional and structural MR image analysis and implementation as FSL. Neuroimage 23 (Suppl 1):S208-S219.
66. Sudo Y, Suhara T, Inoue M, Ito H, Suzuki K, Saijo T, Halldin C, Farde L. 2001. Reproducibility of [11 C]FLB 457 binding in extrastriatal regions. Nucl Med Commun 22:1215-1221.
67. Suhara T, Okubo Y, Yasuno F, Sudo Y, Inoue M, Ichimiya T, Nakashima Y, Nakayama K, Tanada S, Suzuki K, Halldin C, Farde L. 2002. Decreased dopamine D2 receptor binding in the anterior cingulate cortex in schizophrenia. Arch Gen Psychiatry 59:25-30.
68. Suhara T, Sudo Y, Okauchi T, Maeda J, Kawabe K, Suzuki K, Okubo Y, Nakashima Y, Ito H, Tanada S, Halldin C, Farde L. 1999. Extrastriatal dopamine D2 receptor density and affinity in the human brain measured by 3D PET. Int J Neuropsychopharmacol 2:73-82.
69. Talvik M, Nordstrom AL, Olsson H, Halldin C, Farde L. 2003. Decreased thalamic D2/D3 receptor binding in drug-naive patients with schizophrenia: A PET study with [11C]FLB 457. Int J Neuropsychopharmacol 6:361-370.
70. Tsukada H, Miyasato K, Nishiyama S, Fukumoto D, Kakiuchi T, Domino EF. 2005. Nicotine normalizes increased prefrontal cortical dopamine D1 receptor binding and decreased working memory performance produced by repeated pretreatment with MK-801: A PET study in conscious monkeys. Neuropsychopharmacology 30: 2144-2153.
71. Vilkman H, Kajander J, Nagren K, Oikonen V, Syvalahti E, Hietala J. 2000. Measurement of extrastriatal D2-like receptor binding with [11C]FLB 457-a test-retest analysis. Eur J Nucl Med 27:1666-1673.
72. Villemagne VL, Wong DF, Yokoi F, Stephane M, Rice KC, Matecka D, Clough DJ, Dannals RF, Rothman RB. 1999. GBR12909 attenuates amphetamine-induced striatal dopamine release as measured by [(11)C]raclopride continuous infusion PET scans. Synapse 33:268-273.
73. Volkow ND, Wang GJ, Fowler JS, Logan J, Gatley SJ, Hitzemann R, Chen AD, Dewey SL, Pappas N. 1997. Decreased striatal dopaminergic responsiveness in detoxified cocaine-dependent subjects. Nature 386:830-833.
74. Watson C. 2000. New, faster, image-based scatter correction for 3D PET. IEEE Trans Nucl Sci 47:1587-1594.
75. Willeit M, Ginovart N, Graff A, Rusjan P, Vitcu I, Houle S, Seeman P, Wilson AA, Kapur S. 2008. First human evidence of d-amphetamine induced displacement of a D2/3 agonist radioligand: A [11C]-(+)-PHNO positron emission tomography study. Neuropsychopharmacology 33:279-289.
76. Winstanley CA. 2007. The orbitofrontal cortex, impulsivity, and addiction: Probing orbitofrontal dysfunction at the neural, neurochemical, and molecular level. Ann NY Acad Sci 1121:639-655.
77. Wu S, Ogden RT, Mann JJ, Parsey RV. 2007. Optimal metabolite curve fitting for kinetic modeling of 11C-WAY-100635. J Nucl Med 48:926-931.
78. Zhang Y, Brady M, Smith S. 2001. Segmentation of brain MR images through a hidden Markov random field model and the expectation-maximization algorithm. IEEE Trans Med Imaging 20: 45-57.
79. Ziolko S, Narendran R, Becker C, Carmichael O, Frankle WG, Kaye W, Price CJ. 2007. A comparison of automated, fully, deformable atlas-based segmentation and manually drawn striatal volumes of interest as applied to PET scans. Neuroimage S79: 320T-PM.